BQ Prime's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer BQ Prime's subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Securities Report
Tatva Chintan Pharma Chem Ltd.'s Q2 FY23 revenue fell 27.1% YoY and Ebitda plunged 68.9% YoY due to lower structure directing agents sales, which seems very disappointing, but we believe this situation is transitory.
Company expects recovery in SDA sales in Q4 FY23 with revival in heavyduty truck sales in China. Non-SDA business revenue growth was strong, and gross profit margin has been impressive. FY24E outlook is significantly improving on the back of:
commercialisation of flame retardant whose product has been approved by two customers;
intermediate product for which two plants are likely to start in FY24, with more in pipeline;
acceleration in electrolyte salt revenue; and
increasing application of SDA in recycling.
Though the Tatva Chintan Pharma's near-term performance is likely to be weak, potential for the next two years remains very strong in our view, and may surprise on the upside.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
